Latest Imugene (ASX:IMU) News
Page 3
Page 3 of 4
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Imugene Cuts Losses, Boosts Azer-cel Trial with FDA Nod and $25M Raise
25 Feb 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Imugene’s Azer-cel Hits 82% Response Rate, FDA Clears Path for Pivotal Trial
30 Jan 2026
Imugene Gains FDA Nod to Advance Azer-cel into Pivotal Study
8 Dec 2025
FDA Endorses Imugene’s Azer-cel for Pivotal Phase 3 in Hard-to-Treat Lymphoma
8 Dec 2025
Imugene and JW Therapeutics Unite to Target Solid Tumors with Novel ‘Mark and Kill’ Therapy
27 Nov 2025
Imugene’s Azer-cel Trial Hits 81% Response Rate, Raises $25M to Fuel Growth
31 Oct 2025
Imugene Secures $2.42M in Share Purchase Plan After $22.5M Placement
28 Aug 2025
Imugene Cuts FY25 Loss by 54% as Azer-cel Advances with FDA Fast Track
26 Aug 2025
Imugene’s Azer-Cel Shows 75% Response Rate, Backed by $22.5m Capital Raise
31 July 2025
Imugene Unveils $37.5M Equity Raise to Propel Azer-Cel Trials
16 July 2025